Kymera Therapeutics, Inc. Common Stock

Compare this stock

KYMR Stock Report Card

Today's performance

32%

Performance

Score:

10/100

KYMR returned -38.95% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

Score:

69/100

KYMR had a bullish sentiment score of 68.98% across Twitter and StockTwits over the last 12 months. It had an average of 2.55 posts, 2.33 comments, and 0.61 likes per day.

Technicals

Score:

75/100

KYMR receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

Earnings

Score:

10/100

KYMR has missed earnings 11 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 17 quarters, KYMR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score:

47/100

KYMR has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Kymera Therapeutics, Inc. Common Stock Summary

Nasdaq / KYMR

Healthcare

Biotechnology

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Power up your portfolio